Previous Article | Next Article ![]()
Clinical and Diagnostic Laboratory Immunology, March 2000, p. 206-211, Vol. 7, No. 2
Virology Laboratory,
EA-1156,1 and Flow Cytometry
Department,2 Biology Institute of University
Hospital, Nantes, and Viral Immunology Laboratory, CNRS
ESA-5082, Grenoble,3 France
Received 17 September 1999/Returned for modification 10 November
1999/Accepted 6 January 2000
A technique was developed with flow cytometry to quantify the two
immediate-early proteins ZEBRA and Rta, which are involved in the
activation of Epstein-Barr virus replication. We evaluated four
monoclonal antibodies on four cell lines (B95-8, RAJI, Namalwa, and
P3HR1) with varying levels of expression of these replication-phase antigens. The Namalwa lymphoma cell line was used as a negative control. Four fixation-permeabilization procedures were compared. The
preparation of cells with paraformaldehyde and methanol in sequence,
and antigen detection with AZ125 and AR 5A9 monoclonal antibodies, were
found to be the optimal conditions in these cell lines. Our procedure
allowed ZEBRA antigen to be detected in 4.85% of peripheral blood
mononuclear cells from a transplant recipient with a
lymphoproliferative disease.
Epstein-Barr virus (EBV) is the
causative agent of infectious mononucleosis and is associated with
several malignancies (including Burkitt's lymphoma, nasopharyngeal
carcinoma, and immunoblastic lymphomas) in transplant recipients and
patients infected with human immunodeficiency virus (28).
EBV infects normal resting B cells in vitro and activates them in a way
reminiscent of that in which B cells are activated in response to their
cognate antigen. The resulting immortalized lymphoblastoid cell lines
(LCLs) express a well-defined phenotype characterized by the expression
of high levels of activation and adhesion molecules and resemble
lymphoblasts (22). The virus achieves this by encoding six
EBNAs, three latent membrane proteins (LMPs), and two untranslated RNAs
(EBERs), not all of which are essential for immortalization. EBV
remains latent in resting circulating B cells with its genome present
in a limited number of copies as covalently closed episomes. The switch
between latency and replication of EBV is mediated by the BZLF1 gene in the BamHIZ fragment of EBV. The BZLF1-encoded protein
(ZEBRA) is a 38-kDa nuclear protein. Like ZEBRA (or Zta), the R
transactivator (Rta) plays an important role in the switch from latency
to the lytic phase (16). In both epithelial cells and B
lymphocytes (21), Rta alone is capable of disrupting
latency. In other cell types, a combination of ZEBRA and Rta induces
the activation of early viral promoters (2). In studies
based on serological data, we have demonstrated that high titers of
anti-ZEBRA antibodies are to be found both in patients with Hodgkin's
disease (6, 11) and before posttransplant
lymphoproliferative disorders in renal transplant recipients
(5).
The presence of these two immediate-early proteins in the B-cell
lineage, as detected with monoclonal antibodies produced in our
laboratory (3), could thus be evaluated as a marker of virus
replication, possibly associated with tumor progression (13). Infected cells in the peripheral blood of persistently infected healthy individuals are confined to the B-cell lineage and are
present at levels varying between 1 and 50 per 106 B cells
(18). In immunocompromised patients, they are present at
higher levels, e.g., 1 to 10 lytic-infected cells per 104 B
lymphocytes (1, 22), but are rare nevertheless, which makes
them difficult to detect with immunofluorescence under light microscopy. The use of flow cytometry seems a promising alternative in
this context, as it allows a particular cell population (B lymphocytes)
to be first targeted before examining this preselected population for
cells expressing lytic-phase antigens.
The goal of our present study was to assess the feasibility of
detecting lytic-phase EBV antigens with flow cytometry. To this end, we
evaluated different experimental conditions for cell fixation and
permeabilization, and several anti-ZEBRA and anti-Rta antibodies, on
cell lines expressing lytic-phase EBV antigens. Using the conditions
found to be optimal, we then performed some preliminary evaluative
tests on peripheral blood mononuclear cells (PBMCs) from a transplanted
patient with a lymphoproliferative disease.
Cell cultures and lytic-phase antigen chemical induction.
Four cell lines that did or did not express lytic-phase EBV antigens
were purchased from the American Type Culture Collection (Manassas,
Va.). The nonpermissive human Burkitt's lymphoma Namalwa cell line
(CRL-1432) served as a negative control. The human P3HR-1 (HTB-62) and
the marmoset B95-8 lymphoblastoid cell lines are both totally
permissive to the virus, leading to its complete replication. The human
lymphoblastoid RAJI cell line (CCL-86) leads, after stimulation, to
abortive replication (expression of EBV antigens restricted to the
immediate-early phase).
1071-412X/00/$04.00+0
Copyright © 2000, American Society for Microbiology. All rights reserved.
Sequential Use of Paraformaldehyde and Methanol as
Optimal Conditions for the Direct Quantification of ZEBRA and Rta
Antigens by Flow Cytometry
![]()
ABSTRACT
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
INTRODUCTION
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
![]()
MATERIALS AND METHODS
Top
Abstract
Introduction
Materials and Methods
Results
Discussion
References
MAbs. Four monoclonal antibodies (MAbs) were obtained by immunizing BALB/c mice with ZEBRA or Rta recombinant antigens, as previously described (3). MAbs AZ125 and AZ130, both from the immunogloblin G2 (IgG2) subclass, were directed against BZLF1 antigens, while AR5A9 and AR8C12, from the IgG1 subclass, recognized BRLF1 antigens. All MAbs were used as ascitic fluid, and AZ125 and AR5A9 underwent additional purification by affinity chromatography on an A protein column (Fast Flow Laboratories) and were labeled with fluorescein isothiocyanate (FITC).
Fixation, permeabilization, and staining of cultured cells.
Four different procedures for fixation and permeabilization, each
performed on aliquots of 5 × 105 cells, were
evaluated in parallel in the same set of experiments. The techniques
for the paraformaldehyde-methanol (PF/M) method and the
paraformaldehyde-Tween 20 (PF/T) method followed the procedures previously described (8). Briefly, aliquots were incubated 15 min in 1% paraformaldehyde (Merck, Nogent-sur-Marne,
France), washed, and then kept at least 1 h (maximum, 1 month) in
80% methanol at
20°C or incubated overnight at 4°C in 1%
paraformaldehyde supplemented with 0.2% Tween 20 (Sigma). The two
other methods were commercially available: Intraprep
(Immunotech/Coulter, Marseille, France) and Fix&Perm (Caltag/Tebu,
Marnes la Coquette, France). Technical procedures were performed
according to manufacturer's instructions, with incubations with MAbs
performed the same day.
Flow cytometry analysis. Samples were analyzed on a FACScalibur flow cytometer (Becton Dickinson, Mountain View, Calif.). At least 15,000 cells were gated by light scattering and collected in a list mode manner. Percentages of cells expressing EBV lytic-phase antigens and mean fluorescence intensity were determined on FITC histograms for the cell lines and on dot plots of forward side scatter versus FITC fluorescence for the PBMCs from the patient, using a region defined according to the isotype control analysis. All experiments were run in duplicate in two independent series.
Analysis on PBMCs. PBMCs from a nonmyeloablative bone marrow transplant recipient with lymphoproliferative disease (17) were obtained from blood samples collected into an EDTA tube by density gradient centrifugation (Ficoll-Hypaque; Eurobio, Les Ullis, France). PBMCs were then prepared by the PF/M method and stained with MAb AZ125 or IgG2 isotype control, as described for EBV cell lines.
In order to demonstrate viral replication, the presence of ZEBRA mRNA was also determined from RNA extracts obtained from the PBMCs by the RNA-PLUS extraction system (Appligene, Illkirch, France). The BZLF1 reverse transcription-PCR (RT-PCR) assay was carried out in a one-tube reaction with the Superscript one-step RT-PCR system (Life Technologies), with amplification performed as previously described (30).| |
RESULTS |
|---|
|
|
|---|
The technical procedures providing optimal utilization of the four anti-EBV MAbs in flow cytometry were first identified in B95-8 cells cultivated without chemical induction and prepared with paraformaldehyde-methanol. These conditions were then applied to the other cell lines. For the four MAbs used as primary antibodies, incubation at 37°C during 45 min appeared to be adequate (data not shown). No difference was observed when an unpurified MAb was compared with the corresponding FITC-labeled MAb: the optimal concentrations for AZ125 and AR5A9 were, respectively, 1 and 0.5 µg for 5 × 105 cells.
In order to obtain maximum levels of expression of both ZEBRA and Rta
antigens, two chemical induction protocols were evaluated on the four
selected EBV cell lines (Table 1).
Namalwa cells, used as a negative control, never expressed any of the
antigens tested for, as expected. Very mild induction of ZEBRA and Rta expression was observed in RAJI cells stimulated by TPA alone, but the
addition of n-butyrate during chemical induction led to a
10-fold increase in the levels expressed of both antigens. This was
observed with each related MAb. In the two other cell lines (B95-8 and
P3HR1) expressing basically ZEBRA and Rta antigens, incubation with TPA
and n-butyrate induced a three- to fivefold increase of the
percentage of cells expressing both antigens and was associated with a
higher mean fluorescence intensity, especially with MAb AZ125 and MAb
AR5A9.
|
The four protocols for fixation and permeabilization were compared by
running them in parallel with the four cell lines cultivated for 3 days
in the presence of TPA and n-butyrate (Fig.
1). Levels of antigen expression were
assessed with the two MAbs yielding the highest mean fluorescence,
AZ125 and AR5A9, with each of the four fixation-permeabilization
procedures. Namalwa cells never expressed lytic-phase antigens,
whichever protocol was used (data not shown), confirming that no
nonspecific labeling occurred with the two selected MAbs.
|
Cell preparation with paraformaldehyde and Tween 20 always led to a significant underestimation of both ZEBRA and Rta antigens (data not shown). Percentages of cells expressing ZEBRA or Rta were always below 15% for the three cell lines, and related mean fluorescence intensities were less than 50, leading to a poor discrimination between positive and negative cells.
A comparison of the three other fixation-permeabilization procedures used on the three cell lines expressing EBV antigens is shown in Fig. 1. After induction with TPA and n-butyrate, the expression of lytic-phase antigens by B95-8 and P3HR1 cells reached the same level, which was twice that obtained by the RAJI line. It is interesting that, when each procedure for preparing cells of each cell line is considered alone, levels of expression of both ZEBRA and Rta antigens were similar, except for B95-8 cells evaluated with AZ125 on cells prepared with the two commercially available methods. In this cell line, cell preparation with Intraprep or Fix&Perm led to underestimation of ZEBRA expression (17% positive cells; mean fluorescence intensity, 130) in comparison to that obtained with the PF/M method (35% positive cells; mean fluorescence intensity, 160). For the two other cell lines (RAJI and P3HR1), preparation with these two commercially available methods yielded a somewhat higher percentage of cells expressing the two antigens. However, mean fluorescence intensities were still higher when the PF/M method, which allowed better separation between negative and positive cells, was used.
These observations led us to select the PF/M method as the best procedure for preparing cells.
For a preliminary assessment of the feasibility of our technical
procedure in the clinical situation, we tested PBMCs from a patient
with a major EBV lymphoproliferative disorder for ZEBRA antigens.
Occurence of viral replication was assessed by the detection of ZEBRA
RNA messenger in PBMCs (Fig. 2). Flow
cytometry analysis (Fig. 3) also revealed
the presence of ZEBRA antigens in about 5% of this patient's PBMCs.
|
|
| |
DISCUSSION |
|---|
|
|
|---|
EBV has been shown to remain latent in resting B lymphocytes in peripheral blood. This creates a reservoir of virus in contrast to lytic virus replication, which is thought to be restricted to differentiated epithelial cells in vivo. Recent studies using RT-PCR, and immunochemical techniques (20) have demonstrated that B cells in peripheral blood are a major site of virus production during primary infection (for a review, see reference 26). In rare cases, EBV leads to chronic active infection, which is characterized by persistent symptoms and signs of infectious mononucleosis, including persistent B-cell lymphocytosis. In such patients, EBV strains show strongly enhanced activity of the master lytic-phase gene ZEBRA (9). Lytic-cycle replication in reactivated B cells may also be associated with B-cell lymphomas and lymphoproliferative disease (LPD), by shortening tumor latency and increasing the transformation of previously uninfected bystander B cells (23).
We therefore focused our attention on ZEBRA/Rta expression with the versatile FACS methodology. This approach has previously been used in the context of EBV to detect latent or lytic-phase RNA in EBV cell lines by in situ hybridization (4, 12, 27). Some studies have also used flow cytometry to detect EA-D or EA-R, EBV antigens expressed later in the replication cycle (10, 14). One study reported the use of this technology to detect ZEBRA antigens expressed by anti-IgG-stimulated AKATA cells (29). Our aim was to develop and optimize a simple technical procedure for the rapid quantification of immediate-early EBV antigens by flow cytometry.
The first step of our study was to identify which conditions for lytic-phase induction led to the highest levels of antigen expression, which would then allow us to accurately evaluate the optimal conditions for detecting those antigens with flow cytometry. Baseline levels of expression of ZEBRA antigen in the cell lines observed by flow cytometry agreed closely with those obtained with BZ.1 antibody under light microscopy (7). Not surprisingly, stimulation with the TPA plus butyrate combination led to a very significant increase of immediate-early antigens in all three cell lines. In RAJI cells, the procedure caused about 20% of the cells to enter the lytic phase, as previously observed for EA-D (10). We also noted that expression of both Rta and ZEBRA antigens, which are known to be expressed simultaneously (21), reached similar quantitative levels, too.
These findings thus allowed us to evaluate the specificity and reactivity of the four anti-EBV MAbs used in our study. We then decided to retain only two of the four antibodies, AZ125 and AR5A9, which yielded the highest fluorescence intensities and hence allowed better discrimination between nonexpressing and expressing cells.
Selecting and optimizing the techniques used to prepare the cells is a very important step in the adaptation of flow cytometry to herpesvirus antigen detection, since they are located in the nucleus. Four fixation-permeabilization methods were selected and evaluated in parallel. All used paraformaldehyde, which provides good stabilization of permeabilized membranes (preventing the linkage of intracellular proteins with extracellular molecules) and increases the indirect fluorescence of intranuclear antigen (19). For permeabilization, several different reagents were evaluated. Methanol is the most widely used reagent in the study of viral antigens by flow cytometry; it allows such antigens to be conserved over a long period (15) and increases the fluorescence of intracellular antigens (24). The second procedure selected for our study used Tween 20, which provides better preservation both of the staining of surface antigen (important in the selection of B lymphocytes) and of measurements of light scatter (15). Finally, for the two commercially available techniques, Fix&Perm and Intraprep, the exact formulae of the reagents for permeabilization were not disclosed to use by their respective manufacturers, but both contain saponin, whose efficacy in the investigation of nuclear viral antigens has never, to our knowledge, been evaluated.
Of the four procedures we tested, the one using Tween 20 was rapidly
eliminated because it led to a substantial underestimation of antigen
expression levels in all three cell lines. This was probably due to the
fact that Tween 20 produces too gentle a permeabilization of the
membrane and thus does not allow the antibody to reach its nuclear
target (25). The other three techniques led to broadly similar results. With the two techniques using saponin, Fix&Perm and
Intraprep, higher percentages of cells expressing both antigens were
obtained than with the PF/M technique on two of the cell lines, P3HR1
and RAJI. This finding shows that saponin produces satisfactory
permeabilization of the nuclear membranes. However, fluorescence
intensity was lower, which could impair discrimination between positive
and negative cells and lead to a less accurate estimation of the
percentage of cells expressing antigen. Finally, one of the principal
limits of these two techniques from the point of view of routine
laboratory use is that testing cannot be delayed. We therefore opted
for the PF/M technique, which combines the possibility of storing
methanol-treated cells at
70°C for more than a year without
detectable loss of their internal antigen content (15) and
with a greater fluorescence intensity. This technique is also the one
previously chosen for the detection of cytomegalovirus antigen in
polymorphonuclear leukocytes by flow cytometry (8).
Preliminary evaluation of our procedure on PBMCs treated by PF/M was successful, in that we were able to demonstrate ZEBRA expression in the whole PBMCs from a patient with a lymphoproliferative disease. However, it should be noted that this was in the very specific context of extensive lymphoproliferation occurring in a patient who had received a nonmyeloablative allogeneic stem cell transplantation (17).
Our study shows that the use of flow cytometry to detect lytic-phase EBV antigens is feasible. Flow cytometry's main advantages are that it allows objective quantification of cells expressing antigens and it detects low levels of antigen expression with a higher sensitivity than immunomicroscopy. We are currently adapting our technique to quantify B cells in the lytic phase in immunodepressed patients, using a double-labeling procedure. This allows B lymphocytes to be first targeted and then evaluated for EBV antigens. Such an approach has been already successfully applied to the direct quantification of cytomegalovirus antigens in polymorphonuclear cells (8).
| |
FOOTNOTES |
|---|
* Corresponding author. Mailing address: Laboratoire de Virologie EA-1156, Institut de Biologie CHU Nantes, 9 quai Moncousu, 44093 Nantes Cedex, France. Phone: 33/2/40-08-41-23. Fax: 33/2/40-08-41-39. E-mail: bmimbert{at}sante.univ-nantes.fr.
| |
REFERENCES |
|---|
|
|
|---|
| 1. |
Babcock, G. J.,
L. L. Decker,
R. B. Freeman, and D. A. Thorley-Lawson.
1999.
Epstein-Barr virus-infected resting memory B cells, not proliferating lymphoblasts, accumulate in the peripheral blood of immunosuppressed patients.
J. Exp. Med.
190:567-576 |
| 2. |
Bogedain, C.,
P. Alliger,
F. Schwarzmann,
M. Marschall,
H. Wolf, and W. Jilg.
1994.
Different activation of Epstein-Barr virus immediate-early and early genes in Burkitt lymphoma cells and lymphoblastoid cell lines.
J. Virol.
68:1200-1203 |
| 3. |
Brousset, P.,
H. Knecht,
B. Rubin,
E. Drouet,
S. Chittal,
F. Meggetto,
T. Al Saati,
E. Bachmann,
G. Denoyel,
A. Sergeant, and G. Delsol.
1993.
Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease.
Blood
82:872-876 |
| 4. | Crouch, J., D. Leitenberg, B. R. Smith, and J. G. Howe. 1997. Epstein-Barr virus suspension cell assay using in situ hybridization and flow cytometry. Cytometry 29:50-57[CrossRef][Medline]. |
| 5. | Drouet, E., C. Chapuis-Cellier, J. L. Garnier, and J. L. Touraine. 1996. Early detection of Epstein-Barr virus infection and meaning in transplant patients, p. 207-213. In J. L. Touraine, et al. (ed.), Cancer in transplantation. Prevention and treatment. Kluwer Academic Publishers, Dordrecht, Netherlands. |
| 6. | Drouet, E., P. Brousset, F. Fares, J. Icart, C. Verniol, F. Meggetto, D. Schlaifer, H. Desmorat-Coat, F. Rigal-Huguet, A. Niveleau, and G. Delsol. 1999. High Epstein-Barr virus serum load and elevated titers of anti-ZEBRA antibodies in patients with EBV-harboring tumor cells of Hodgkin's disease. J. Med. Virol. 57:383-389[CrossRef][Medline]. |
| 7. |
Flamand, L.,
I. Stefanescu,
D. V. Ablashi, and J. Menezes.
1993.
Activation of the Epstein-Barr virus replicative cycle by human herpesvirus 6.
J. Virol.
67:6768-6777 |
| 8. | Imbert-Marcille, B.-M., N. Robillard, A.-S. Poirier, M. Coste-Burel, D. Cantarovich, N. Milpied, and S. Billaudel. 1997. Development of a method for direct quantification of cytomegalovirus antigenemia by flow cytometry. J. Clin. Microbiol. 35:2665-2669[Abstract]. |
| 9. | Jager, M., N. Prang, M. Mitterer, C. Larcher, H. P. Huemer, U. Reischl, H. Wolf, and F. Schwarzmann. 1996. Pathogenesis of chronic Epstein-Barr virus infection: détection of virus strain with high rate of lytic replication. Br. J. Haematol. 95:626-36[CrossRef][Medline]. |
| 10. |
Jenson, H. B.,
G. M. Grant,
Y. Ench,
P. Heard,
C. A. Thomas,
S. G. Hilsenbeck, and M. P. Moyer.
1998.
Immunofluorescence microscopy and flow cytometry characterization of chemical induction of latent Epstein-Barr virus.
Clin. Diagn. Lab. Immunol.
5:91-97 |
| 11. | Joab, I., J. C. Nicolas, G. Schwaab, G. De The, G. Clausse, M. Perricaudet, and Y. Zeng. 1991. Detection of anti-Epstein-Barr virus transactivation (ZEBRA) antibodies in sera from patients with nasopharyngal carcinoma. Int. J. Cancer 48:647-649[Medline]. |
| 12. | Just, T., H. Burgwald, and M. Kjaervig Broe. 1998. Flow cytometry detection of EBV (EBERs mRNA) using peptide nucleic acid probe. J. Virol. Methods 73:163-174[CrossRef][Medline]. |
| 13. | Katz, B. Z., N. Raab-Traub, and G. Miller. 1989. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative disease. J. Infect. Dis. 160:589-598[Medline]. |
| 14. | Lidin, B., L. Gartland, G. Marshall, V. Sanchez, and E. W. Lamon. 1993. Detection of two early gene products of Epstein-Barr virus by fluorescence flow cytometry. Viral Immunol. 6:97-107[Medline]. |
| 15. |
Mc Sharry, J.
1994.
Uses of flow cytometry in virology.
Clin. Microbiol. Rev.
7:576-604 |
| 16. | Miller, G. 1990. The switch between latency and replication of Epstein-Barr virus. J. Infect. Dis. 161:833-844[Medline]. |
| 17. | Milpied, N., M. Coste-Burel, F. Accard, A. Moreau, P. Moreau, R. Garand, and J.-L. Harousseau. 1999. Epstein-Barr virus associated B-cell lymphoproliferative disease after non myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant. 23:629-630[CrossRef][Medline]. |
| 18. | Miyashita, E. M., B. Yang, K. M. Lam, D. H. Crawford, and D. A. Thorley-Lawson. 1995. A novel form of Epstein-Barr virus latency in normal B cells in vivo. Cell 80:595-601. |
| 19. | Pollice, A., J. McCoy, S. Shackney, C. Smith, J. Agarwal, D. Burholt, L. Janocko, F. Hornicek, S. Singh, and R. Hartsock. 1992. Sequential paraformaldehyde and methanol fixation for simultaneous flow cytometric analysis of DNA, cell surface proteins, and intracellular proteins. Cytometry 13:432-444[CrossRef][Medline]. |
| 20. |
Prang, N. S.,
M. W. Hornef,
M. Jager,
H. J. Wagner,
H. Wolf, and F. M. Schwarzmann.
1997.
Lytic replication of Epstein-Barr virus in the peripheral blood: analysis of viral gene expression in B lymphocytes during infectious mononucleosis and in normal carrier state.
Blood
89:1665-1677 |
| 21. |
Ragoczy, T.,
L. Heston, and G. Miller.
1998.
The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes.
J. Virol.
72:7978-7984 |
| 22. | Rickinson, A. B., and E. Kieff. 1996. Epstein-Barr virus, p. 2397-2446. In B. N. Fields, D. M. Knipe, and P. M. Howley (ed.), Fields virology, 3rd ed. Lippincott-Raven Publishers, Philadelphia, Pa. |
| 23. | Rochford, R., and D. E. Mosier. 1995. Differential Epstein-Barr virus gene expression in B-cell subsets recovered from lymphomas in SCID mice after transplantation of human peripheral blood lymphocytes. J. Virol. 69:150-155[Abstract]. |
| 24. | Schimenti, K., and J. Jaccobberger. 1992. Fixation of mammalian cells for flow cytometric evaluation of DNA content and nuclear immunofluorescence. Cytometry 13:48-59[CrossRef][Medline]. |
| 25. | Schmid, I., H. Uittenbogaart, and J. Giorgi. 1991. A gentle fixation and permeabilization method for combined cell surface and intracellular staining with improved precision in DNA quantification. Cytometry 12:279-285[CrossRef][Medline]. |
| 26. | Schwarzmann, F., M. Jager, M. Hornef, N. Prang, and H. Wolf. 1998. Epstein-Barr viral gene expression in B-lymphocytes. Leuk. Lymphoma 30:123-129[Medline]. |
| 27. | Stowe, R. P., M. L. Cubbage, C. F. Sams, D. L. Pierson, and A. D. T. Barrett. 1998. Detection and quantification of Epstein-Barr virus EBER1 in EBV-infected cells by fluorescent in situ hybridization and flow cytometry. J. Virol. Methods 75:83-91[CrossRef][Medline]. |
| 28. |
Straus, S. E.,
J. I. Cohen,
G. Tosato, and J. Meier.
1993.
Epstein-Barr virus infections: biology, pathogenesis, and management.
Ann. Intern. Med.
118:45-58 |
| 29. | Takase, K., C. A. Kelleher, N. Terada, J. F. Jones, J. J. Lucas, and E. W. Gelfand. 1996. Dissociation of EBV genome replication and host cell proliferation in anti-IgG-stimulated Akata cells. Clin. Immunol. Immunopathol. 81:168-174[CrossRef][Medline]. |
| 30. |
Tierney, R. J.,
N. Steven,
L. S. Young, and A. B. Rickinson.
1994.
Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state.
J. Virol.
68:7374-7385 |
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»